查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1825536

2025年可逆性氣道疾病治療全球市場報告

Reversible Airway Diseases Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

可逆性呼吸道疾病治療市場預計將在未來幾年強勁成長，到2029年將達到1,187.6億美元，年複合成長率（CAGR）為6.9%。預測期間的成長主要受人口老化、慢性病盛行率上升、都市化和空氣污染以及醫療保健覆蓋率擴大等因素所驅動。預測期內的主要趨勢包括數位健康技術、新治療方法的研發、早期療育和預防以及吸入器技術的進步。

未來五年6.9%的成長率預測比我們先前的預測略有下降0.1%。這一下降主要源自於美國與其他國家之間關稅的影響。預計關稅壁壘將阻礙美國，因為它會增加來自印度和荷蘭的霧化器和支氣管擴張吸入器的成本，從而延緩氣喘和慢性阻塞性肺病（COPD）症狀的緩解，並增加呼吸系統醫療設備支出。由於互惠關稅以及貿易緊張局勢和限制措施升級對全球經濟和貿易的負面影響，關稅壁壘的影響也將更加廣泛。

慢性呼吸系統疾病的日益流行預計將在未來幾年推動可逆性氣道疾病治療市場的成長。呼吸系統疾病影響呼吸系統，包括肺部、支氣管、氣管、喉、咽和鼻腔。慢性呼吸系統疾病的檢測和治療能夠以及早發現和診斷急性呼吸窘迫症候群等疾病，降低併發症的風險並有助於防止病情惡化。例如，2024 年 2 月，英國政府機構英國衛生安全局報告稱，從 2022 年到 2023 年，英格蘭的結核病病例增加了 10.7%，從 4,380 例增加到 4,850 例。這意味著一年內肺結核發生率顯著增加。因此，慢性呼吸系統疾病的增加預計將推動可逆性氣道疾病治療市場的擴張。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球可逆性氣道疾病治療：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球可逆性氣道疾病治療市場：成長率分析
  • 全球可逆性氣道疾病治療市場表現：規模與成長，2019-2024
  • 全球可逆性氣道疾病治療市場預測：規模與成長，2024-2029年，2034年
  • 全球可逆性呼吸道疾病治療：總目標市場（TAM）

第6章 市場細分

  • 全球可逆性氣道疾病治療市場：依療法、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 胸部X光相片
  • 電腦斷層掃描（CT）
  • 肺部治療
  • 外科移植
  • 製藥
  • 全球可逆性氣道疾病治療市場：按疾病、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 氣喘
  • 慢性支氣管炎
  • 氣腫
  • 囊腫纖維化
  • 細支氣管炎
  • 其他疾病
  • 全球可逆性氣道疾病治療市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 專科診所
  • 其他最終用戶
  • 全球可逆性氣道疾病治療市場：胸部X光相片細分（按類型）、績效及預測，2019-2024年、2024-2029年、2034年
  • 標準胸部X光檢查
  • 數位化胸部X光
  • 全球可逆性氣道疾病治療市場：按電腦斷層掃描 (CT) 掃描類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 高解析度電腦斷層掃描
  • 螺旋電腦斷層掃描
  • 全球可逆性氣道疾病治療市場：依肺部治療（類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 吸入療法
  • 肺康復
  • 氧氣療法
  • 全球可逆性氣道疾病治療市場：依外科植入物細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 肺移植
  • 支氣管鏡檢查
  • 其他外科手術
  • 全球可逆性氣道疾病治療市場：依藥物類型、績效及預測細分，2019-2024 年、2024-2029 年、2034 年
  • 支氣管擴張劑
  • 皮質類固醇
  • 抗膽鹼藥物
  • 其他藥物

第7章 區域和國家分析

  • 全球可逆性氣道疾病治療市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球可逆性氣道疾病治療市場：國家、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 可逆性氣道疾病治療市場：競爭格局
  • 可逆性氣道疾病治療市場：公司簡介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Sanofi SA
  • GlaxoSmithKline Plc
  • Medtronic plc
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Grifols SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dragerwerk AG & Co. KGaA
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年可逆性氣道疾病治療市場：提供新機會的國家
  • 2029年可逆性氣道疾病治療市場：細分市場帶來新機會
  • 2029年可逆性氣道疾病治療市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r28898u

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $85.53 billion in 2024 to $90.91 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $118.76 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of nebulizers and bronchodilator inhalers sourced from India and the Netherlands, thereby delaying asthma/COPD symptom relief and elevating pulmonology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market in the coming years. Respiratory diseases are conditions impacting the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Testing and treatment for chronic respiratory diseases enable early detection and diagnosis of conditions such as acute respiratory distress syndrome, helping to prevent progression by reducing the risk of complications. For example, in February 2024, the UK Health Security Agency, a government agency in the United Kingdom, reported a 10.7% increase in tuberculosis (TB) cases in England from 2022 to 2023, rising from 4,380 cases to 4,850. This represents a significant increase in TB incidence over the year. Consequently, the rise in chronic respiratory diseases is expected to fuel the expansion of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

Leading companies in the reversible airway disease treatment market are increasingly focusing on inhalational dosage forms in respiratory drug delivery to maintain their market position. For example, in May 2022, Alkem, a pharmaceutical company based in India, launched the Innohaler, a dry powder inhaler (DPI) device. This device is designed to improve life for patients with asthma and COPD by addressing significant gaps in asthma care within India. With the Innohaler, Alkem is stepping into the core inhalation therapeutics market, ensuring that each dose reaches the lungs efficiently. Furthermore, the device is supported by programs promoting patient awareness and adherence, maximizing its impact.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major companies operating in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited.

North America was the largest region in the reversible airway diseases treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Reversible Airway Diseases Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for reversible airway diseases treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The reversible airway diseases treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment : Chest X Ray; Computed Tomography (CT) Scan; Lung Therapies; Surgery Transplant; Medications
  • 2) By Diseases: Asthma; Chronic Bronchitis; Emphysema; Cystic Fibrosis; Bronchiolitis; Other Diseases
  • 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
  • 2) By Computed Tomography (CT) Scan: High-Resolution CT Scan; Spiral CT Scan
  • 3) By Lung Therapies: Inhalation Therapy; Pulmonary Rehabilitation; Oxygen Therapy
  • 4) By Surgery Transplant: Lung Transplant; Bronchoscopic Procedures; Other Surgical Interventions
  • 5) By Medications: Bronchodilators; Corticosteroids; Anticholinergics; Other Medications
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; GlaxoSmithKline Plc; Medtronic plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Grifols SA; Sumitomo Dainippon Pharma Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Dragerwerk AG & Co. KGaA; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Getinge AB; Hikma Pharmaceuticals plc; Amneal Pharmaceuticals LLC; Lupin Limited; Fisher & Paykel Healthcare Corporation Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Reversible Airway Diseases Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Reversible Airway Diseases Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Reversible Airway Diseases Treatment Market Growth Rate Analysis
  • 5.4. Global Reversible Airway Diseases Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Reversible Airway Diseases Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Reversible Airway Diseases Treatment Total Addressable Market (TAM)

6. Reversible Airway Diseases Treatment Market Segmentation

  • 6.1. Global Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chest X Ray
  • Computed Tomography (CT) Scan
  • Lung Therapies
  • Surgery Transplant
  • Medications
  • 6.2. Global Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Asthma
  • Chronic Bronchitis
  • Emphysema
  • Cystic Fibrosis
  • Bronchiolitis
  • Other Diseases
  • 6.3. Global Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users
  • 6.4. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard Chest X-Ray
  • Digital Chest X-Ray
  • 6.5. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Computed Tomography (CT) Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • High-Resolution CT Scan
  • Spiral CT Scan
  • 6.6. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Lung Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Inhalation Therapy
  • Pulmonary Rehabilitation
  • Oxygen Therapy
  • 6.7. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of By Surgery Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Transplant
  • Bronchoscopic Procedures
  • Other Surgical Interventions
  • 6.8. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bronchodilators
  • Corticosteroids
  • Anticholinergics
  • Other Medications

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

  • 7.1. Global Reversible Airway Diseases Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Reversible Airway Diseases Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Reversible Airway Diseases Treatment Market

  • 8.1. Asia-Pacific Reversible Airway Diseases Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Reversible Airway Diseases Treatment Market

  • 9.1. China Reversible Airway Diseases Treatment Market Overview
  • 9.2. China Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Reversible Airway Diseases Treatment Market

  • 10.1. India Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Reversible Airway Diseases Treatment Market

  • 11.1. Japan Reversible Airway Diseases Treatment Market Overview
  • 11.2. Japan Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Reversible Airway Diseases Treatment Market

  • 12.1. Australia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Reversible Airway Diseases Treatment Market

  • 13.1. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Reversible Airway Diseases Treatment Market

  • 14.1. South Korea Reversible Airway Diseases Treatment Market Overview
  • 14.2. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Reversible Airway Diseases Treatment Market

  • 15.1. Western Europe Reversible Airway Diseases Treatment Market Overview
  • 15.2. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Reversible Airway Diseases Treatment Market

  • 16.1. UK Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Reversible Airway Diseases Treatment Market

  • 17.1. Germany Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Reversible Airway Diseases Treatment Market

  • 18.1. France Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Reversible Airway Diseases Treatment Market

  • 19.1. Italy Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Reversible Airway Diseases Treatment Market

  • 20.1. Spain Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Reversible Airway Diseases Treatment Market

  • 21.1. Eastern Europe Reversible Airway Diseases Treatment Market Overview
  • 21.2. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Reversible Airway Diseases Treatment Market

  • 22.1. Russia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Reversible Airway Diseases Treatment Market

  • 23.1. North America Reversible Airway Diseases Treatment Market Overview
  • 23.2. North America Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Reversible Airway Diseases Treatment Market

  • 24.1. USA Reversible Airway Diseases Treatment Market Overview
  • 24.2. USA Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Reversible Airway Diseases Treatment Market

  • 25.1. Canada Reversible Airway Diseases Treatment Market Overview
  • 25.2. Canada Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Reversible Airway Diseases Treatment Market

  • 26.1. South America Reversible Airway Diseases Treatment Market Overview
  • 26.2. South America Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Reversible Airway Diseases Treatment Market

  • 27.1. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Reversible Airway Diseases Treatment Market

  • 28.1. Middle East Reversible Airway Diseases Treatment Market Overview
  • 28.2. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Reversible Airway Diseases Treatment Market

  • 29.1. Africa Reversible Airway Diseases Treatment Market Overview
  • 29.2. Africa Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Reversible Airway Diseases Treatment Market Competitive Landscape
  • 30.2. Reversible Airway Diseases Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. GlaxoSmithKline Plc
  • 31.3. Medtronic plc
  • 31.4. Eli Lilly and Company
  • 31.5. Gilead Sciences Inc.
  • 31.6. Amgen Inc.
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Grifols SA
  • 31.11. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Dragerwerk AG & Co. KGaA
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

34. Recent Developments In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Reversible Airway Diseases Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Reversible Airway Diseases Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Reversible Airway Diseases Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer